There are 410 resources available
Invited Discussant 13MO, 14MO, 15MO and 16MO
Presenter: Marina Garassino
Session: Mini Oral 2
Resources:
Slides
Webcast
Welcome and introduction
Presenter: Maurice Perol
Session: Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy
Resources:
Webcast
Antibody-drug conjugates: Current perspectives
Presenter: Antonio Passaro
Session: Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy
Resources:
Webcast
Antibody-drug conjugates: Future considerations
Presenter: Enriqueta Felip
Session: Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy
Resources:
Webcast
Introduction and first vote
Presenter: Silvia Novello
Session: Is there a place for conformal PORT in 2023?
Resources:
Slides
Webcast
7MO - Sotorasib in <italic>KRAS</italic> G12C–mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)
Presenter: Natalie Maimon
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
Yes
Presenter: Dirk De Ruysscher
Session: Is there a place for conformal PORT in 2023?
Resources:
Slides
Webcast
Case presentation of young patient with EGFR-mutant resected NSCLC (stage pT2pN1)
Presenter: Alfredo Addeo
Session: Optimal duration of adjuvant TKI
Resources:
Slides
Webcast
8MO - Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
Presenter: Pasi Jänne
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
No
Presenter: Cécile Le Pechoux
Session: Is there a place for conformal PORT in 2023?
Resources:
Slides
Webcast